Since EVs/GHCer-mediated angiogenesis is linked to TRAX/PLCβ1/Ca2+ signaling pathway, development of novel anti-cancer drugs that could disrupt the GHCer/TRAX interaction may provide a new strategy for the treatment of GHCer-positive cancer. The gene discussed is PLCB1; the disease is cancer.